Monitoring of tumor response to cisplatin with simultaneous fluorescence and positron emission tomography: a feasibility study.

Dual modality molecular imaging can capture concurrent molecular events and evaluate therapeutic efficacy from uniquely different perspectives based on different molecular targets. In this work, dual modality tomographic imaging, (18) F-fluorodeoxyglucose based positron emission tomography and subsurface fluorescence molecular tomography ([(18) F]FDG-PET/subsurface FMT), is proposed to monitor tumor response to cisplatin on a mouse xenograft model in vivo. One mouse was administered with cisplatin (1.0 mg/kg) by intraperitoneal injection once every day for 14 days, and another mouse was administered with saline to serve as the control. Dual modality [(18) F]FDG-PET/subsurface FMT imaging was conducted on days 0, 2, 5, 9, 15, and 22. In vivo imaging and quantitative analysis demonstrated the feasibility of [(18) F]FDG-PET/subsurface FMT imaging in tracking the changes of [(18) F]FDG tumor uptake and amount of red fluorescent protein (RFP) synthesized by tumor cells in the same mouse simultaneously. Dual modality [(18) F]FDG-PET/subsurface FMT imaging may thus provide a powerful tool for better understanding disease progress and treatment evaluation from different perspectives.

[1]  单保慈,et al.  An advanced fully 3D OSEM reconstruction for positron emission tomography , 2010 .

[2]  Jianwen Luo,et al.  Monitoring of tumor response to cisplatin by subsurface fluorescence molecular tomography. , 2012, Journal of biomedical optics.

[3]  R. Moats,et al.  In vivo Near-Infrared Fluorescence Imaging of Integrin αvβ3 in Brain Tumor Xenografts , 2004, Cancer Research.

[4]  Anna Moore,et al.  Multiparametric monitoring of tumor response to chemotherapy by noninvasive imaging. , 2009, Cancer research.

[5]  Michael E Phelps,et al.  Impact of animal handling on the results of 18F-FDG PET studies in mice. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  R. Weissleder,et al.  Near-infrared fluorescent imaging of tumor apoptosis. , 2003, Cancer research.

[7]  Ralph Weissleder,et al.  Near-infrared optical imaging of proteases in cancer. , 2003, Molecular cancer therapeutics.

[8]  S. Moon,et al.  Comparison of the Intraperitoneal, Retroorbital and per Oral Routes for F-18 FDG Administration as Effective Alternatives to Intravenous Administration in Mouse Tumor Models Using Small Animal PET/CT Studies , 2011, Nuclear medicine and molecular imaging.

[9]  H. Shimada,et al.  Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Baoci Shan,et al.  A Dual Modality System for Simultaneous Fluorescence and Positron Emission Tomography Imaging of Small Animals , 2011, IEEE Transactions on Nuclear Science.

[11]  J Nuyts,et al.  18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). , 2003, European journal of cancer.

[12]  Ralph Weissleder,et al.  Improved detection of ovarian cancer metastases by intraoperative quantitative fluorescence protease imaging in a pre-clinical model. , 2009, Gynecologic oncology.

[13]  E. Aboagye,et al.  Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. , 2005, Cancer research.

[14]  John C Gore,et al.  Molecular Imaging of Therapeutic Response to Epidermal Growth Factor Receptor Blockade in Colorectal Cancer , 2008, Clinical Cancer Research.

[15]  Vasilis Ntziachristos,et al.  Looking and listening to light: the evolution of whole-body photonic imaging , 2005, Nature Biotechnology.

[16]  Xin Liu,et al.  Extraction of target fluorescence signal from in vivo background signal using image subtraction algorithm , 2012, Int. J. Autom. Comput..

[17]  Sanjiv S Gambhir,et al.  Preclinical Efficacy of the c-Met Inhibitor CE-355621 in a U87 MG Mouse Xenograft Model Evaluated by 18F-FDG Small-Animal PET , 2007, Journal of Nuclear Medicine.

[18]  Baoci Shan,et al.  Simultaneous fluorescence and positron emission tomography for in vivo imaging of small animals. , 2011, Journal of biomedical optics.

[19]  Edward W. Larsen,et al.  Light transport in biological tissue based on the simplified spherical harmonics equations , 2006, J. Comput. Phys..

[20]  Michael E. Phelps,et al.  Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase Inhibitors , 2006, Clinical Cancer Research.

[21]  Wolfgang A Weber,et al.  Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Chatziioannou,et al.  Tomographic bioluminescence imaging by use of a combined optical-PET (OPET) system: a computer simulation feasibility study , 2005, Physics in medicine and biology.

[23]  S. Gambhir,et al.  Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.

[24]  Guobao Wang,et al.  Three-dimensional fluorescence optical tomography in small-animal imaging using simultaneous positron-emission-tomography priors. , 2009, Optics letters.

[25]  J. Bai,et al.  In-vivo fluorescence molecular tomography based on optimal small animal surface reconstruction , 2010 .

[26]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[27]  Chun Li,et al.  Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. , 2003, Cancer research.